Novo Nordisk (China) Pharmaceuticals Co., Ltd. (the “Company”) is committed to providing high quality drugs and devices to patients and to safeguarding high standards of patient safety. Recently the company was contacted by a handful of patients stating that the NovoNorm® tablets they had bought from local pharmacies appeared different to their usual NovoNorm®tablets. Following an investigation, Novo Nordisk has identified that these few tablets are not drugs produced by the company but are counterfeit tablets. Novo Nordisk has reported these incidents of counterfeit NovoNorm® tablets incidences to the Chinese regulatory authorities local FDA, and an investigation has subsequently been carried out by the relevant related local authorities.
Should patients be concerned their NovoNorm®tablets are counterfeit, the company has provided the following information in order to assist in distinguishing genuine NovoNorm®products from counterfeits. Should any products be suspected of being counterfeit after comparison with the information below, we highly recommend you immediately contact your local regulatory authorities and to the company.
This is the first time that Novo Nordisk has encountered counterfeit
NovoNorm® tablets since it was launched in China more than
10 years ago. The Company is highly committed to working with local
regulatory authorities to fight counterfeit products, in order to
safeguard the health of patients.